Monte Rosa Operating Income Over Time
| GLUE Stock | USD 18.61 0.65 3.62% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Monte Rosa Performance and Monte Rosa Correlation. Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.32 | Revenue Per Share | Quarterly Revenue Growth 0.385 | Return On Assets | Return On Equity |
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Monte Rosa Therapeutics and related stocks such as Day One Biopharmaceu, Arvinas, and Replimune Group Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (13.8 M) | (72.7 M) | (146.9 M) | (206.1 M) | (217.3 M) | (127.8 M) | (134.1 M) |
| ARVN | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (24.8 M) | (43.8 M) | (51.5 M) | (124.9 M) | (195.3 M) | (263.2 M) | (401.5 M) | (250.2 M) | (114.9 M) | (120.6 M) |
| REPL | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (19.2 M) | (30.9 M) | (56.2 M) | (82.8 M) | (121.5 M) | (177.1 M) | (234.8 M) | (261.6 M) | (235.5 M) | (223.7 M) |
| TBPH | (109.3 M) | (109.3 M) | (9.6 M) | (156.3 M) | (232.5 M) | (181.9 M) | (180.5 M) | (260.1 M) | (238.8 M) | (251.9 M) | (297.6 M) | (257.8 M) | (92 M) | (56 M) | (46.9 M) | (42.3 M) | (44.4 M) |
| AVBP | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (36.9 M) | (74.6 M) | (94.3 M) | (94.3 M) | (84.9 M) | (89.1 M) |
| GERN | (12.2 M) | (96.1 M) | (71.8 M) | (39 M) | (36.3 M) | (559 K) | (30.6 M) | (29.3 M) | (31.1 M) | (72.5 M) | (76.9 M) | (114 M) | (138.6 M) | (193.9 M) | (173.7 M) | (53.8 M) | (56.5 M) |
| VIR | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (118.7 M) | (178 M) | (297 M) | 420.8 M | 833.1 M | (684.3 M) | (587.2 M) | (468 M) | (444.6 M) |
| DNA | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (137 M) | (1.8 B) | (2.2 B) | (864.4 M) | (559.8 M) | (315.3 M) | (331 M) |
| VALN | (1.4 M) | (4.5 M) | (12.8 M) | (20.9 M) | (23.8 M) | (19.9 M) | (42.6 M) | (4 M) | 6.3 M | (811 K) | (55.1 M) | (61.4 M) | (113.4 M) | (82.1 M) | 13.3 M | 12 M | 12.6 M |
| MGTX | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (31.7 M) | (78.1 M) | (58.3 M) | (62.6 M) | (72.8 M) | (116.4 M) | (137.1 M) | (164.2 M) | (147.8 M) | (140.4 M) |
Monte Rosa Therapeutics and related stocks such as Day One Biopharmaceu, Arvinas, and Replimune Group Operating Income description
Operating Income is the amount of profit realized from Monte Rosa Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Monte Rosa Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Monte Rosa Therapeutics | GLUE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 321 Harrison Avenue, |
| Exchange | NASDAQ Exchange |
USD 18.61
Check out Monte Rosa Performance and Monte Rosa Correlation. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Monte Rosa technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.